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Abstract Objective Nausea and vomiting are the most
distressful side effects of cytotoxic drugs in cancer patients.
Antiemetics are commonly used to reduce these side
effects. However, the current antiemetic efficacy is about
70–80% in patients treated with highly-emetogenic cyto-
toxic drugs. One of the potential factors explaining this
suboptimal response is variability in genes encoding
enzymes and proteins which play a role in metabolism,
transport and receptors related to antiemetic drugs. Aim of
this review was to describe the pharmacology and phar-
macogenetic concepts of of antiemetics in oncology.
Method Pharmacogenetic and pharmacology studies of
antiemetics in oncology published between January 1997
and February 2010 were searched in PubMed. Furthermore,
related textbooks were also used for exploring the phar-
macology of antiemetic drugs. The antiemetic drugs which
were searched were the 5-hydroxytryptamine 3 receptor
antagonists (5-HT3RAs), dopamine antagonists, cortico-
steroids, benzodiazepines, cannabinoids, antihistamines
and neurokinin-1 antagonists. Result The 5-HT3RAs are
widely used in highly emetogenic chemotherapy in com-
bination with dexamethasone and a neurokinin-1 antago-
nist, especially in acute phase. However, the dopamine
antagonists and benzodiazepines were found more appro-
priate for use in breakthrough and anticipatory symptoms
or in preventing the delayed phase of chemotherapy
induced nausea and vomiting. The use of cannabinoids and
antihistamines need further investigation. Only six articles
on pharmacogenetics of the 5-HT3RAs in highly emeto-
genic chemotherapy are published. Specifically, these
studies investigated the association of the efficacy of
5-HT3RAs and variants in the multi drug resistance 1
(MDR1) gene, 5-HT3A,B and C receptor genes and
CYP2D6 gene. The pharmacogenetic studies of the other
antiemetics were not found in this review. Conclusion It is
concluded that pharmacogenetic studies with antiemetics
are sparse. It is too early to implement results of pharma-
cogenetic association studies of antiemetic drugs in clinical
practice: confirmation of early findings is required.
Keywords Anti-emetic agents  Cancer 
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Impact of findings on practice
• Since only limited pharmacogenetic studies on antie-
metic drugs in oncology are known, the clinician’s
decision regarding antiemetic treatment are currently
based on patient’s risk factors and emetogenicity of
chemotherapeutic drugs rather than on genetic variants
affecting antiemetic drug reponse.
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• Genetic variants should only be considered in case of
suboptimal antiemetic response in patients treated with
highly emetogenic chemotherapy.
• Other investigators may be encouraged to conduct
pharmacogenetic studies on antiemetic drug treatment
in oncology.
Introduction
Chemotherapy induced nausea and vomiting (CINV) are
the most distressing side effects in cancer patients treated
with chemotherapy and can have a negative impact on the
patients’ quality of life [1]. Moreover, CINV can seriously
influence patients’ adherence to chemotherapy [2] and may
thus influence progression free survival and overall sur-
vival. In the past, before using standard anti-emetic drug
regimens, nausea and vomiting resulted in up to 20% of
patients in delay or refusal of chemotherapy [3]. Highly
effective anti-emetic drugs are available nowadays and
their standardized use increases patients’ quality of life [4].
However, in patients receiving highly-emetogenic cyto-
toxic drug therapy the proportion of patients experiencing
effective anti-emetic therapy is only 70–80% [5]. One of
the factors responsible for variable response to anti-emetic
drugs is the inter-individual difference in biotransforma-
tion. Moreover, polymorphisms in genes encoding drug
receptors related to the anti-emetic drugs along with other
patient related risk factors such as gender, age, and drug
related factors such as emetogenic potential of chemo-
therapy may explain inter-individual differences in anti-
emetic drug response [6].
Objective
The aim of this paper is to review the mechanism of action
and pharmacology and the potential role of pharmacoge-
netics of anti-emetic drugs in oncology.
Methods
Studies on the pharmacology and pharmacogenetics of the
5-hydroxytryptamine 3 receptor antagonists (5-HT3RAs),
dopamine antagonists, corticosteroids, benzodiazepines,
cannabinoids, antihistamines and neurokinin-1 antagonists
were searched in PubMed January 1997 to February 2010.
In addition, pharmacology textbooks were also reviewed to
summarize the mechanism and pharmacological effects of
antiemetics.
Result
Pharmacogenetic studies of antiemetics in oncology are
scarce and the individual studies are relatively small: in
four studies more than 200 patients, in one study 120
patients and in one study 70 patients were included. These
studies investigated the pharmacogenetics of 5-HT3RAs in
Multi Drug Resistence1 (MDR1) gene, 5-HT3 A,B and C
receptor genes and the CYP2D6 gene. The summary of
these studies is listed in Table 1. Furthermore, more arti-
cles related with mechanism and pharmacologicy effect
were found in this review. The mechanism of antiemetics
are listed in Fig. 1. The mechanism and pharmacology
effect of antiemetics will be discussed below.
Discussion
Chemotherapy induced nausea and vomiting (CINV)
Based on the emetogenic potential, cytotoxic drugs are
classified into several categories: (1) highly-emetogenic,
which can cause symptoms in [90% patients without
anti-emetic drug treatment, (2) moderate risk, which can
cause symptoms in 30–90% of patients (3) low risk with
10–30% of symptomatic patients and (4) minimally
emetogenic with \10% of symptomatic patients. Table 2
lists the emetogenic categories for various chemothera-
peutic agents [7].
Emetogenicity includes both onset and duration of
nausea and vomiting [2]. In patients receiving a combina-
tion of cytotoxic drugs, the classification of emetogenicity
is based on the cytotoxic drug with the greatest emetogenic
potential [8]. Specifically, for defining the emetogenicity of
combination regimens of cytotoxic drugs which required a
more intensive antiemetic prophylaxis and therapy, the
following situations may occur: (1) the minimal emeto-
genic agent does not contribute to the emetogenicity of the
combined regimen, (2) the low emetogenic agents will
increase the emetogenicity of the combined regimen by one
level greater than the most emetogenic agent in the regi-
men, (3) the moderately and highly emetogenic agents will
increase the emetogenicity of each drug in the combined
regimen by one level [9], e.g. combination of doxorubicin
and cyclophosphamide are highly emetogenic, although
both drugs alone are classified as moderate.
CINV is categorized as acute (occurring within 24 h of
therapy], delayed (persisting for 6–7 days after therapy) or
anticipatory (occurring prior to chemotherapy administra-
tion). Breakthrough nausea and vomiting refer to uncon-
trollable symptoms and need rescue anti-emetics despite
the use of prophylactic anti-emetics. Some patients also
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experience refractory nausea and vomiting when they did
not receive adequate control of nausea and vomiting in
prior cycles [2].
Cytotoxic drugs can cause emesis through stimulation
in the neuron-anatomical centers: (1) the emetic center,
(2) the area postrema or chemoreceptor trigger zone
(CTZ), and (3) the vagal nerve afferents [10]. The CTZ is
sensitive to chemical stimuli, and is the main site of
action of anti-emetic drugs [11]. However, the blood–
brain barrier which is closely located to the CTZ is per-
meable allowing circulating mediators to act directly to
the emetic center [11]. However, newer insight from
animal studies suggest that an anatomically discrete
vomiting center is unlikely to exist. Rather, a number of
loosely organized neuronal areas within the medulla
probably interact to coordinate the emetic reflex. The
neurons coordinating the complex series of events that
occur during emesis have been termed the ‘‘central pat-
tern generator.’’ Also, free radical formation appear to
have an important role in the induction of nausea and
vomiting [12]. The most important neurotransmitters
which involve in emetic process are dopamine, serotonin
and substance P. However, the receptors 5-HT1A, 2A,
2C, 3A, 3B,4, receptors CB1 and a adrenergic are also
known to be involved in emesis mechanism [13]. More-
over, l-opioid receptors are also thought to be involved in
mediating anti-emetic effect in humans [14].
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Fig. 1 Activation of emetic pathway by cytotoxic drugs and site of
action of ant-emetic drugs. Adapted from [10, 26, 58]. 5-HT 5
Hydroxytriptamin, D2 dopamine, SP substance P, H histamine,
M muscarinic, CTZ chemoreceptor trigger zone, VAP vagal afferent
pathway, 5-HT3RA 5-HT3 receptor antagonist. Emesis pathway solid
arrow. Sites of action of drugs dotted arrow
Table 1 Pharmacogenetic studies of anti-emetics
Drugs target (author, year of
publication)
Gene Endpoint N Results
Ondansetron or tropisetron
Kaiser et al. (2002), [20]
CYP2D6 Nausea and vomiting on highly
emetogenic cytotoxic drug
270 UMs demonstrate the highest incidence and severity
of nausea and vomiting. Frequency of UMs was
1.5%.
Ondansetron or tropisetron
Tremblay et al. (2003), [52]
5-HT3B
receptor
Nausea and vomiting on high
emetogenic cytotoxic drug
286 5-HT3B receptor gene may serve as genetic
predictor for anti-emetic therapy with the _AAG
deletion variant (OR = 32) after adjusted with
other risk factors of emesis.
Tropisetron
Kaiser et al. (2004), [6]
5-HT3A
receptor
Nausea and vomiting on high
emetogenic cytotoxic drug
242 There were 21 polymorphisms in 5-HT3A receptor
gene, whereas the 15 polymorphisms had partial
linkage each of them. The haplotypes in these
genes did not have significant association with
chemotherapy induced nausea and vomiting.
Tropisetron, granisetron,
ondansetron.
Babaoglu et al. (2005), [57]
ABCB 1
(MDR 1)
Nausea and vomiting on high
emetogenic cytotoxic drug
216 The complete control rate of nausea and vomiting
was higher in subjects with ABCB1 TT genotype
as compared with those with TC or CC genotype
(92.9% vs. 56.1% vs. 47.6%, P = 0.044)
Ondansetron
Fasching et al. (2008), [54]
5-HT3C
receptor
Nausea and vomiting on moderate
emetogenic cytotoxic drug
120 Variant genotype of K163 N was associated with
vomiting (RR = 2.62)
Dolasetron or tropisetron
Ward et al. (2008), [53]
5-HT3C
receptor
Nausea and vomiting on high
emetogenic cytotoxic drug
70 5-HT3C receptor gene may not serve as genetic
predictor for anti-emetic therapy
UMs: Ultra-rapid metabolizers
5-HT3A: 5-Hydroxytriptamine 3A
5-HT3B: 5-Hydroxytriptamine 3B
5-HT3C: 5-Hydroxytriptamine 3C
ABCB1: ATP Binding Casette, subfamily B, member 1
MDR1: Multi-Drug Resistence 1
Int J Clin Pharm
123
The majority of dopamine, serotonin and substance P
receptors are found in the dorsal vagal complex, the area
postrema and in the gastrointestinal tract. After cytotoxic
drugs have passed through the blood stream to the gas-
trointestinal tract, they can cause damage to the entero-
chromaffin cells. This damage causes subsequent release of
5-HT3 and stimulates the CTZ and vomiting center via
5HT3 receptors. Ultimately, this causes contraction of
abdominal muscles, diaphragm, stomach and esophagus
activation and an emetic response [10]. The mechanism of
CINV is depicted in Fig. 1.
5-HT3 receptors are located centrally in the CTZ of
the area postrema and peripherally in the vagal nerve ter-
minals. Activation of the vomiting center is caused by
direct stimulation of 5-HT3 receptors in the CTZ by
cytotoxic drugs. Equally, stimulation of vagal afferents will
be transmitted to the vomiting center through nucleus
tractus solitarius [15]. Five different 5-HT3 receptors are
known in humans, 5-HT3A, B, C, D and E. 5-HTR3A,
5-HTR3B and 5-HTR3C are expressed in the CNS as well
as in the vagal nerve terminals, whereas 5-HTR3D is pre-
dominantly and 5-HTR3E is exclusively expressed in the
gastrointestinal tract. The 5-HT3A and 5-HT3B receptor
may be involved in the mechanism of CINV [16].
Delayed and acute emesis mechanism are thought to be
different. Acute emesis is mainly stimulated by serotonin
whereas dopamine and histamine are thought to contribute
to delayed emesis. Some inflammation mediators, such as
prostaglandine, histamine and substance P are involved in
visceral inflammation which results in delayed emesis [10].
Otherwise, the Positron Emesis Tomography (PET), could
be also useful to investigate the future pathophysiology of
nausea and vomiting, especially in delayed emesis,
refractory emesis and emesis during multiple cycles of
chemotherapy [17].
Pharmacology of anti-emetic drugs
5-Hydroxytryptamine 3 receptor antagonists [5-HT3RAs]
The 5-HT3RAs are the standard anti-emetic treatment for
acute CINV in patients treated with moderately to highly
emetogenic chemotherapy. It has been demonstrated that
their use in combination with a corticosteroid results in
complete protection of acute CINV in 70–80% of patients
receiving highly emetogenic chemotherapy [18, 19]. The
5-HT3RAs bind selectively and competitively to 5-HT3
receptors thereby blocking the emetogenic signals to the
vomiting center [15].
Several 5-HT3RAs, such as dolasetron, granisetron,
ondansetron, tropisetron and palonosetron are available
[16]. Table 3 shows the pharmacological characteristics of
these 5-HT3RAs.
Generally, the 5-HT3RAs are well absorbed from the
gastrointestinal tract and undergo first-pass metabolism
after oral administration. The prodrug dolasetron is rapidly
metabolized by carbonyl reductase to its active form, hy-
drodolasetron which is 70% bound to plasma proteins. This
active metabolite is further metabolized mainly by cyto-
chrome P450 [CYP] 2D6 [15].
Granisetron is metabolized by the liver through
N-demethylation, aromatic ring oxidation, and conjugation
Table 2 Emetogenicity of chemotherapeutic agents (Adapted from
[7])
Emetogenic potential Cytotoxic drug Dosage
High Cisplatin [1,500 mg/m2
Cyclophosphamide
Dacarbazine
Mechloretamine
Carmustine
Streptozotocin
Moderate Cyclophosphamide \1,500 mg/m2
Carboplatin
Doxorubicin
Cytarabine [1,000 mg/m2
Oxaliplatin
Ifosfamide
Daunorubicin
Epirubicin
Idarubicin
Irinotecan
Low Paclitaxel
Docetaxel
Mitoxantrone
Topotecan
Etoposide
Pemetrexed
Methotrexate
Mitomycin
Gemcitabine [1,000 mg/m2
Cytarabine
5-Fluorouracil
Bortezomib
Cetuximab
Trastuzumab
Minimal Bleomycin
Busulfan
2-Chlorodeoxyadenosine
Fludarabine
Vinblastine
Vincristine
Vinorelbine
Bevacizumab
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mediated by the P450 CYP3A and CYP1A1 isoenzymes
which is different from the other 5-HT3RAs. Ondansetron
is 70–76% bound to plasma protein and is extensively
metabolized by CYP3A4 in the liver by hydroxylation of
the indole ring followed by glucuronide or sulfate conju-
gation. Tropisetron is metabolized mainly by the liver P450
CYP2D6 isoenzyme through oxidative hydroxylation of
the indole ring followed by conjugation with glucuronic
acid or sulfate which are excreted by the kidneys [15, 20].
Palonosetron is 62% bound to plasma proteins. Palo-
nosetron’s total clearance is lower than the other
5-HT3RAs resulting in a relatively long plasma elimination
half life [21]. Palonosetron is metabolized mainly by
CYP2D6 (50%) and followed by CYP3A and CYP1A2
mediated metabolism [15].
Granisetron, ondansetron and palonosetron have slightly
different receptor specificity. Palonosetron is a highly
selective, high affinity competitive antagonist of the
5-HT3A receptor, whereas granisetron is highly specific for
all subtypes of 5-HT3 receptors but has little or no affinity
for 5-HT1, 5-HT2 and 5-HT4 receptors. Ondansetron also
binds to the 5-HT1B, 5-HT1C, a1 adrenergic and l-opioid
receptors. The clinical relevance of these findings is not
clear [15]. Despite the fact that ondansetron has different
affinity to 5-HT3B,1B,1C, a-adrenergic and l- opioid
receptors as compared to granisetron, many studies have
shown that this not imply differential efficacy between
ondansetron and granisetron [13].
Dopamine antagonists
The exact mechanism of action of the dopamine antago-
nists prochlorperazine and metoclopramide as anti-emetic
drugs is unclear, but prochlorperazine inhibits apomor-
phine induced vomiting by blocking dopamine D2 recep-
tors [DRD2] in the CTZ. Also metoclopramide has shown
to directly affect the CTZ in the area postrema by blocking
DRD2. The drug increases the CTZ threshold and decrea-
ses the sensitivity of visceral nerves that transmit afferent
impulses from the gastrointestinal tract to the vomiting
center in the lateral reticular formation [22].
The phenothiazine derivative prochlorperazine is pri-
marily metabolized in the liver via hydroxylation, oxida-
tion, demethylation, sulfoxide formation and conjugation
with glucuronic acid. The oxidative reactions are catabo-
lized by CYP2D6. Metoclopramide is also metabolized by
the liver and its metabolites are excreted in the urine and
feces [22, 23]. CYP2D6 plays a major role in metoclo-
pramide metabolism, thus poor metabolizer of CYP2D6
may have slower elimination of metoclopramide [24]. Also
the buthyrophenone haloperidol shows extensive hepatic
metabolism with CYP3A4 being the main enzyme
involved, [25, 26].
Corticosteroids
Corticosteroids such as dexamethasone are potent anti-
emetics and are used in combination with other agents.
Their anti-emetic mechanism of action is uncertain but it is
assumed that it involves inhibition of the prostaglandin
synthesis in the hypothalamus [26].
Corticosteroids are metabolized in most tissues, but
primarily in the liver through glucuronidation and sulfox-
idation pathways to biologically inactive compounds [22].
Dexamethasone and methylprednisolon are substrates of
CYP3A4 [13].
Benzodiazepines
The anti-emetic mechanism of action of benzodiazepines,
for example lorazepam, is related to the combination
effects of sedation, reduction in anxiety, and possibly
depression of the vomiting centre [22, 26].
Benzodiazepines bind to plasma protein, varying from
70–99%, and undergo extensive metabolism by CYP
enzymes [27]. The CYP2C19 and CYP3A4/5, CYP2C9
and CYP1A2 contribute to the metabolism of
benzodiazepines.
Table 3 Pharmacokinetic characteristics of 5-HT3 receptor antagonists. Adapted from [13, 20, 49, 59]
Ondansetron Dolasetron Granisetron Tropisetron Palonosetron
Oral bioavailability 60–70% 76% 60% 60% 97%
Volume of distribution 1.8 L/kg 5.8 L/kg 3.0 L/kg 5.7–8.6 L/kg 8.3 L/kg
Metabolism CYP1A1a CYP2D6 CYP3A4/5 CYP2D6 CYP2D6
CYP1A2 CYP3A/4/5 CYP1A1 CYP3A/4/5a CYP1A2a
CYP2D6 CYP3A/4/5a
CYP3A/4/5
t1/2 elimination in healthy patients (hours) 3.5–5.5 6.9–7.3 4.9–7.6 5.7 24–64.2
t1/2 elimination in cancer patients (hours) 4 7.5 9–11 8 128
a Minor
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Cannabinoids
Cannabinoids have an anti-emetic effect at the entero-
chromaffin cells in the gastrointestinal tract and an anti-
cholinergic effect on cholinergic terminals and Auerbach’s
plexus and possibly mediate the prostaglandin cyclic
nucleotide system [26]. Two cannabinoid drugs, dronabinol
and nabilone, have been approved for CINV. Although
there are conflicting data, cannabinoids can be used for
refractory emesis [23, 28, 29]. Nabilone showed superior
efficacy compared to prochlorperazine and also the com-
bination of the two agents were better than was used alone
[30]. The use of these agents is limited because of their
slow elimination from the body and because of adverse
effects such as sedation, dysphoria, vertigo, euphoria,
dizziness, and dry mouth [29]. Cannabinoids are prone to
pharmacodynamic and/or pharmacokinetic interactions
with other drugs. The interaction of cannabinoids with
chemotherapeutic agents that are sensitive to the alteration
of CYP3A function should be closely monitored [31].
Antihistamines
The pharmacological effect of the anti-emetic drug
dimenhydrinate is conceived as result of its diphenhydra-
mine moiety. Dimenhydrinate and meclizine have CNS
depressant, anti-cholinergic, anti-emetic, antihistamines
and local anesthetic effects. Although its anti-emetic
mechanism of action is unclear, dimenhydrinate has been
shown to inhibit vestibular stimulation, acting first on the
otolith system and in larger doses on the semicircular
canals. Dimenhydrinate inhibits acetylcholine and it is
proposed that this is the primary mechanism of action.
Dimenhydrinate is widely distributed into body tissues, and
is metabolized by the liver via CYP450, but limited
information is available on which specific isoenzyme is
involved [22].
Neurokinin-1 antagonist
Aprepitant is a neurokinin-1 receptor antagonist and
inhibits the action of substance P in the emetic pathways
both centrally and peripherally. Substance P, neurokinin-A
(NK-A) and neurokinin-B (NK-B) are members of the
tachykinin family. These peptides are mediated through
three receptors: NK-1, NK-2, NK-3. Substance P displays
the strongest affinity for NK-1, whereas NK-A and NK-B
have strong affinity for NK-2 and NK-3 [32]. Recently,
substance P has shown to have a role in emesis, especially
in delayed emesis [33].
Aprepitant is highly bound to plasma proteins ([95%)
and has an elimination half life of 9–13 h making it suit-
able for once daily administration. Aprepitant is both a
substrate and a moderate inhibitor of CYP3A4. In addition,
aprepitant also induces CYP2C9 and CYP3A4 and there-
fore may be prone to drug-drug interactions [32].
Casopitant, a new yet unapproved neurokinin-1 receptor
antagonist, has an oral clearance of 24.4 L/h/kg in female
patients and this agent is both a substrate and weak to
moderately inhibitor of CYP3A4 [34].
Variable efficacy of anti-emetics
According to the guideline of the American Society of
Clinical Oncology on prevention of CINV, the combination
of neurokinin-1 receptor antagonist, 5-HT3RA and dexa-
methasone is the regimen of choice in patients receiving
highly emetogenic chemotherapy. Moreover, addition of
lorazepam or alprazolam, or substitution the 5-HT3RA
with high dose intravenous of metoclopramide or adding
dopamine antagonist is recommended in patients with
suboptimal response [7, 8].
5-Hydroxytryptamine 3 receptor antagonists [5-HT3RAs]
The use of 5-HT3RAs and the combination with dexa-
methasone results in complete acute emesis protection in
70% of patients receiving a first cycle of highly emetogenic
chemotherapy. However, they are not very effective in the
delayed phase of emesis. Indeed, even following complete
protection in the acute phase, 40% of patients experience
delayed symptoms of emesis, which interfere with quality
of life. In the outpatients setting, the symptoms may be
underestimated by health care professionals [2].
Tropisetron, ondansetron and granisetron are considered
to have similar efficacy which is supported by several
clinical studies. A Turkish study showed that the complete
response rate of these drugs in combination with dexa-
methasone in the control of acute emesis was 80% for
tropisetron 72% for ondansetron and 72% for granisetron
(P = 0.877). These three drugs also appeared to have
similar side-effect profiles [35].
Palonosetron was found to be effective in preventing
delayed CINV and it was approved by FDA as the first
anti-emetic drug for preventing both acute and delayed
CINV [10]. It has a higher binding affinity and longer
elimination half life as compared to the other 5-HT3RAs
due to its unique structural characteristics based on a fused
tricyclic ring system [36, 37]. The use of palonosetron,
aprepitant and dexamethasone as a single day regimen of
anti-emetic combination in cancer patients receiving
cyclophosphamide and/or doxorubicin resulted in complete
protection in 51% of patients with 76% of patients in acute
phase and 66% of patients in delayed phase of emesis [38].
The use of this combination in Japanese patients showed
protection in 75% of patients in the acute phase compared
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with 73% in the granisetron group. During the delayed
phase 57% of patients had complete response in the palo-
nosetron group compared to 45% of patients in granisetron
group [39].
Ramosetron and azasetron are the newest agents of
5-HT3RA. In cancer patients receiving highly and mod-
erately emetogenic chemotherapy, the combination of
intravenous ramosetron and dexamethasone showed 77%
of complete response in comparison with granisetron and
dexamethasone which had 82% of complete response [40].
Azasetron, in combination with olanzapine and dexa-
methasone could improve the complete antiemetic
response of cancer patients in the delayed phase. In this
study the combination of azasetron -dexamethasone and
olanzapine-azasetron-dexamethasone was compared in
patients receiving highly and moderately emetogenic che-
motherapy [41].
Dopamine antagonists
Metoclopramide is still used for breakthrough CINV
symptoms and as adjunctive medications in building anti-
emetic regimens for patients with refractory nausea and
vomiting. Prochlorperazine has similar efficacy as ondan-
setron plus dexamethasone in preventing delayed nausea
vomiting on days 2–5 [42]. However, the use of metaclo-
pramide in pediatric and elderly patients is not recom-
mended because of the high incidence of dystonic reactions
[8, 43].
Corticosteroids
The complete response rates of dexamethasone are about
15–20% higher when it was added to 5-HT3RAs. Dexa-
methasone is effective in prevention of CINV in both the
acute phase and delayed phase. Corticosteroids are some-
times underutilized because of their potential adverse
effects. Because the anti-emetic use of corticosteroids is
short term, tapering the dose is rarely needed [29].
Benzodiazepines
Benzodiazepines, especially lorazepam are being used for
patients with breakthrough symptoms and anticipatory
symptoms of CINV [8, 23]. Olanzapine can improve both
patients’ quality of life and patients’ complete response in
delayed nausea vomiting during the treatment of highly or
moderate emetogenic cytostatics [41]. In a phase II study,
the combination of olanzapine, dexamethasone and palo-
nosetron was effective in controlling acute nausea and
vomiting in patients receiving highly and moderately
emetogenic cytostatics [44].
Cannabinoids
Nabilone as anti-emetic was superior to placebo, domper-
idone and prochlorperazine in preventing CINV, but not
superior not metoclopramide or chlorpromazine. Nabilone
also did not increase the benefit of 5-HTRAs as anti-emetic
in CINV [45].The use of cannabinoids and olanzapine have
been suggested as potentially useful interventions, but data
from phase III clinical trials are still lacking [46].
Antihistamines
Diphenhydramine or hydroxyzine in the prevention of
CINV have not shown any anti-emetic activity. Antihista-
mines have a role in the treatment of nausea thought to be
mediated by the vestibular system [3].
NK-1 antagonist
There is evidence to support the use of a three-drug regi-
men for prevention of acute emesis in highly emetic regi-
mens as a minimum standard of care, including a
5-HT3RA, a neurokinin-1 antagonist (NK-1A) and dexa-
methasone [10, 11]. A randomised phase II study of the
NK-1 antagonist aprepitant in patients receiving cisplatin
showed a complete protection in the NK-1 antagonist arm
of the study of 93% for acute emesis and 83% for delayed
emesis compared to 67% for acute emesis and 37% of
delayed emesis with granisetron and dexamethasone. The
addition of aprepitant to the 5-HT3RA and dexamethasone
can improve the acute emesis protection by a further
10–15% and 20–30% in the delayed phase of emesis [19].
The efficacy of casopitant was shown in study com-
paring the combination of casopitant-ondansetron-dex-
amethasone and ondansetron-dexamethasone. The addition
of casopitant could increase the complete antiemetic
response at 120 h by 20% in cancer patients receiving
highly emetogenic chemotherapy [47].
Aprepitant is not available in some countries, and the
5-HT3RAs are relatively expensive and may therefore not
be an option for some patients. Other agents such as pro-
chlorperazine, nabilone, dronabinol and olanzapine may be
added, however no studies are available on the efficacy and
safety of these combinations [46].
General remark concerning variable clinical efficacy
of anti-emetic drugs
The effectivity of anti-emetic treatment is also influenced
by factors such as age of the patients, history of alcohol
intake, type of cancer, chemotherapy regimen and course
of chemotherapy. There are data available from gynaeco-
logical cancer patients showing that younger patients who
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received cisplatin regimen experience significant lower
rates of nausea and vomiting complete responses. How-
ever, patients with the first three course of chemotherapy
had significant higher complete response with regard to
nausea than those with chemotherapy after the third course
[48]. The 5-HT3RAs with long duration of action, low risk
of drug-drug interactions and once daily dosing are pre-
ferred [49]. Combination of palonosetron and dexametha-
sone shows no significant differences in complete response
and complete control of emesis in elderly patients (C65
years) as compared to non-elderly patients (\65 years) who
received high and moderate emetogenic cytostatic agent
(P = 1.00) [50]. In cancer patients with multiple-day che-
motherapy, the efficacy of the combination of palonosetron
and dexamethasone is not significantly different compared to
ondansetron and dexamethasone in prevention of delayed
emesis. Nevertheless, patients still need rescue anti-emetic
treatment to a considerable extent [37]. Female gender and a
history of motion sickness is positively related to efficacy to
prevent nausea in patients receiving combination of
5HT3RA and dexamethasone. In addition, patients with a
history of low chronic alcohol intake experienced more post
chemotherapy vomiting [51].
Pharmacogenetic studies of anti-emetics
Differential responses of patients to anti-emetic drugs can
be due to factors such as age, gender, and variations in the
activity of enzymes, which are involved in the uptake,
binding, activation or degradation of these drugs. Table 1
summarizes the published pharmacogenetic studies of anti-
emetics. The pharmacogenetic studies about DRD2
antagonists related with their usage as anti-emetics are not
found. No pharmacogenetic studies on corticosteroids used
as anti-emetic are known.
Pharmacogenetic studies exploring variation in genes
encoding drug receptors
Tremblay et al. [52] performed a pharmacogenetic study in
German Caucasian cancer patients (n = 242), who
received moderately to highly emetogenic cytostatic drug
regimens. Prophylactic tropisetron or ondansetron during
chemotherapy was given to the patients. In total, 13 poly-
morphisms in the 5-HT3B receptor gene were studied and
the frequencies of these variants ranged from 0.4 to 0.7%.
Homozygotes for the -100_-102AGG deletion variant in
the promoter region of 5-HT3B receptor gene experienced
significantly more vomiting and nausea. Patients homozy-
gous for the -100_-102AGG deletion variant of the 5-HT3B
receptor gene showed the highest intensity of vomiting and
nausea after chemotherapy, whereas the patients having the
wild type showed the lowest score [mean value of episodes
of vomiting in the first observation period of 1 ± 0.58 vs.
0.23 ± 0.07; P = 0.02]. The intensity of vomiting of het-
erozygous carriers of the deletion variant was in between
the intensity of vomiting observed in the homozygous
mutant and the wild type carriers. The Odds Ratio (OR) for
nausea and vomiting was 0.5 [95% CI: 0.1–3.2] in the
heterozygous carriers of the deletion variant and 32 in
homozygous carriers of the deletion variant [95% CI:
2.5–422) after adjustment for the other predictors of nausea
and vomiting, such as age, female gender, glucocorticoids
usage, and the variant of CYP2D6. However, the frequency
of the heterozygous genotype for the deletion variant is
approximately 20% whereas the frequency of the homo-
zygous genotype is only 1.3%. Moreover, the data warrant
confirmation with larger sample sizes.
Kaiser et al. [6], investigated polymorphisms of the
5-HT3A receptor in 242 Caucasian cancer patients with
various emetogenic treatments. They included 21 poly-
morphisms with an allele frequency of the variant ranging
from 0.2 to 31.1% in their study. The number of patients
suffering from nausea was 35.9% and higher than the
number of patients with emesis (23.7%). No significant
association between efficacy and genetic variants was
found. Only patients with the heterozygous Met257Ile
polymorphism showed a non-significantly lower intensity
of nausea and vomiting compared to wild type patients.
However, the frequency of the Met257Ile variant is very
low and there was no single individual homozygous for the
Met allele. The 5819G [ A polymorphism showed a non-
significant higher intensity of nausea and vomiting com-
pared to patients homozygous for the G allele. The authors
suggest to consider a combination of individual risk factors
such as age, gender, the emetogenicity level of cytotoxic
drug and the polymorphism of CYP2D6, as a predictor of
emesis risk while a single genetic polymorphism in the
5-HT3A receptor gene may not serve as a pharmacogenetic
predictor of anti-emetic treatment with 5-HT3RAs in can-
cer patients [6].
A study on polymorphisms of the 5-HT3C receptor gene
in 70 Caucasian cancer patients receiving dolasetron or
ondansetron was performed by Ward et al. [53]. The study
revealed seven novel variants in the 5-HT3C gene with
allele frequencies ranging from 1.4 to 42.9%. The common
polymorphisms were 6342C [ T, 7051G [ A and
7142G [ C. There were no statistically significant associ-
ations between either isolated variants or haplotypes and
anti-emetic efficacy. About 18.6% of patients failed to
achieve the optimal protection and 28.6% of patients
experienced nausea. This study concluded that genetic
variants of the 5-HT3C receptor genes may not be pre-
dictive for anti-emetic response of the used drugs .
Fasching et al. [54] studied 120 Caucasian cancer
patients receiving a combination of ondansetron-
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dexamethasone before anthracycline chemotherapy. They
explored 1 SNP in 5-HT3B receptor gene (Y129S) and 2
SNPs in 5-HT3C receptor gene (A405G and K163 N) with
an allele frequency ranging from 29.9 to 62.1%. The
Y129S and A405G showed no significant association with
the complete response of emesis. However the K163 N
variant was found to be significantly associated with a
higher percentage of non responders. Wild type and het-
erozygous patients were reported to have a vomiting epi-
sode rate of 22%, whereas homozygous patients were
reported to have a vomiting episode in 50% of the patients.
The homozygous variants of K163 N had hazard ratio of
3.35 (95% CI: 1.00–11.25) in comparison with the het-
erozygous patients in acute emesis. Therefore, the HTR3C
gene could serve as a predictive factor for CINV in patients
undergoing moderately emetogenic chemotherapy.
Pharmacogenetic studies exploring variation in genes
encoding enzymes involved in drug metabolism
The highly polymorphic cytochrome P450 mono-oxygen-
ase system in the liver is involved in the metabolism of
many drugs. About 20 to 25% of all drugs in clinical use
are metabolized at least in part by CYP2D6 [55]. CYP2D6
activity may be classified into one of four categories: (1)
poor metabolizers (PM), (2) intermediate metabolizers
(IM), (3) extensive metabolizers (EM), (4) ultrarapid
metabolizers (UM) [52]. The majority of the Caucasian
population is classified into EM, 5–10% are PM, approxi-
mately 2% are UM whereas less than 2% of Asians were
found to be PM and more than 50% were found to be EM
[15, 53]. The frequency of dysfunctional CYP2D6 alleles
in Asians is 50% and higher than in Caucasians (29%).
Therefore, many Asians, including Japanese, Chinese and
Malay, metabolize CYP2D6 mediated drugs more slowly
than Caucasians, because of predominantly CYP2D6*10, a
highly frequent reduced function allele. Kaiser et al. [20]
studied the clinical impact of genetic polymorphisms in the
CYP2D6 gene on 5-HT3RAs response in cancer patients.
Caucasian patients who were UMs had more vomiting
within the first 4-h (P = 0.001) and within the 5–24 h
period (P = 0.03) when given ondansetron and tropisetron
as prophylactic therapy. This result was supported by the
observation that tropisetron is primarily dependent on the
CYP2D6 isoenzyme for metabolism. The frequency of
UMs in Caucasians is low (1.5%) and the study must be
confirmed with larger sample sizes to define the contribu-
tion of genotyping.
In a study investigating patients’ response to ondanse-
tron prophylaxis for post-operative nausea and vomiting
(n = 250), there were significant differences of vomiting
incidence in PM, IM, EM and UM (8, 17, 15 and 45%,
P \ 0.01) but not in nausea incidence [56].
Variation in genes encoding drug transporters
A study in cancer patients (n = 216) receiving high or
moderate emetogenic cytostatic drugs which were given
prophylactic tropisetron, ondansetron or granisetron was
performed to explore an association of ABCB1
3435C [ T polymorphism with clinical resistance to
5-HT3RAs. Overall the proportion of patients who were
protected from nausea and vomiting was about 60% in the
acute phase and 50% in the delayed phase of chemotherapy.
Patients who were homozygous for the ABCB1 3435T allele
responded better to anti-emetic therapy [92.9%] compared
with individuals who were heterozygous (56.1%) or
homozygous for the ABCB1 3435C allele (47.6%) in the
acute phase (P = 0.044). This difference reached statistical
significance in the granisetron-treated group. However, no
statistically significant differences were found in the
patients treated with tropisetron or ondansetron, which is
surprising since ondansetron is known to be transported by
ABCB1 whereas tropisetron is not. It is likely that patients
with the TT genotype accumulate higher concentrations of
5-HT3RAs in the brain and may benefit more from
5-HT3RA treatment. During the delayed phase of chemo-
therapy, there were no differences in the proportion of
complete control of emesis across the genotype groups
(P = 0.53). The findings of this study need to be confirmed
in a cohort treated with a more homogeneous chemothera-
peutic regimen and at a larger sample size [57].
Conclusion
Despite a wide armamentarium of antiemetic drugs a
considerable number of cancer patients treated with eme-
togenic chemotherapy experience nausea and vomiting.
Pharmacogenetics may help to individualize anti-emetic
treatment however this field is relatively unexplored.
Interestingly, drug transporters, metabolism and receptor
target pathways of 5HT3RAs are known to be polymorphic
and have shown to be related to efficacy of 5-HT3RAs.
However, it is too early to implement the results of the
various studies into clinical practice. Additional large
studies also considering non-genetic risk factors are
warranted.
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